Company | Name | Exchange | Sector | Industry | 3 Month | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ABVC Biopharma | NASDAQ | Healthcare | Biotechnology & Medical Research | 334.4% | US$64.52M | -7.9x | -0.26 | US$3.97 | 18.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Metaplanet | OTC Markets | 276.5% | US$7.03B | 336.1x | 3.93 | US$10.56 | -0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||||
IREN Ltd | NASDAQ | Technology | Financial Technology (Fintech) & Infrastructure | 188.3% | US$3.93B | -45.5x | 1.86 | US$16.23 | -4.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 32.5% Upside | Upgrade to Pro+ | |
Nuscale Power | NYSE | Utilities | Electrical Utilities & IPPs | 147.4% | US$5B | -17x | 0.73 | US$37.48 | 4.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -3.9% Downside | Upgrade to Pro+ | |
Robinhood Markets | NASDAQ | Technology | Financial Technology (Fintech) & Infrastructure | 125.1% | US$86.78B | 54.7x | 0.05 | US$98.34 | -0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 0.6% Upside | Upgrade to Pro+ | |
Coinbase Global | NASDAQ | Technology | Financial Technology (Fintech) & Infrastructure | 120.5% | US$98.59B | 65.8x | 13.14 | US$387.06 | -0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -24.4% Downside | Upgrade to Pro+ | |
ProQR Therapeutics NV | NASDAQ | Healthcare | Biotechnology & Medical Research | 107.1% | US$244.40M | -6.2x | 4.02 | US$2.32 | -1.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Septerna | NASDAQ | Healthcare | Biotechnology & Medical Research | 105.1% | US$522.67M | -3.1x | 0.06 | US$11.73 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Ascentage Pharma | NASDAQ | Healthcare | Biotechnology & Medical Research | 104.5% | US$3.34B | -30.1x | -1 | US$38.24 | -6.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -26.8% Downside | Upgrade to Pro+ | |
D Wave Quantum | NYSE | Technology | Software & IT Services | 104.3% | US$4.68B | -25.5x | 2.32 | US$14.81 | -7.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 21.5% Upside | Upgrade to Pro+ | |
Ast Spacemobile | NASDAQ | Technology | Telecommunications Services | 95.8% | US$11.32B | -25.5x | 0.4 | US$45.58 | 3.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -0.4% Downside | Upgrade to Pro+ | |
Argo Corp | OTC Markets | Technology | Software & IT Services | 91.9% | US$57.75M | -0.06 | US$0.42 | -4.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Phathom Pharma | NASDAQ | Healthcare | Pharmaceuticals | 88.1% | US$639.37M | -1.8x | 0.11 | US$9.18 | -5.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
51Talk Online Education DRC | NYSE | Academic & Educational Services | Miscellaneous Educational Service Providers | 86.6% | US$168.28M | -37x | -0.5 | US$28.72 | -1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Futu | NASDAQ | Technology | Financial Technology (Fintech) & Infrastructure | 86.6% | US$20.88B | 24.7x | 0.43 | US$149.99 | 4.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -0.1% Downside | Upgrade to Pro+ | |
Yuanbao | NASDAQ | 79.1% | US$1.29B | 6.5x | 0.05 | US$28.59 | -3.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||||
Hims Hers Health | NYSE | Healthcare | Healthcare Providers & Services | 75.9% | US$10.72B | 63.7x | 0.01 | US$47.89 | -4.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -8.1% Downside | Upgrade to Pro+ | |
CureVac NV | NASDAQ | Healthcare | Biotechnology & Medical Research | 71.2% | US$1.23B | 5.8x | 0.04 | US$5.46 | 0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -4% Downside | Upgrade to Pro+ | |
Kuros Biosciences | OTC Markets | Healthcare | Biotechnology & Medical Research | 69.3% | US$1.36B | -281.9x | -4.22 | US$35.55 | -0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Stoke Therapeutics | NASDAQ | Healthcare | Biotechnology & Medical Research | 68.9% | US$647.52M | 13.6x | 0.09 | US$11.86 | -1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Blueprint Medicines Corp | NASDAQ | Healthcare | Biotechnology & Medical Research | 59.9% | US$8.37B | -52.7x | -1.12 | US$129.30 | -0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -0.2% Downside | Upgrade to Pro+ | |
Gold Royalty | NYSE | Financial | Investment Banking & Investment Services | 59.9% | US$414.28M | -122.8x | -1.44 | US$2.43 | 2.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 19.3% Upside | Upgrade to Pro+ | |
Astera Labs | NASDAQ | Technology | Semiconductors & Semiconductor Equipment | 59.5% | US$15.82B | 280x | 3.46 | US$95.90 | -1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 4.3% Upside | Upgrade to Pro+ | |
Arrowhead Pharma | NASDAQ | Healthcare | Biotechnology & Medical Research | 55.3% | US$2.53B | -16.1x | -0.24 | US$18.31 | -2.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Sailfish Royalty | OTC Markets | Basic Materials | Metals & Mining | 52.8% | US$136.05M | 165.9x | 0.92 | US$1.82 | 6.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Himalaya Shipping | NYSE | Industrials | Freight & Logistics Services | 48.1% | US$312.42M | 20.1x | 0.14 | US$6.78 | 2.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 29.4% Upside | Upgrade to Pro+ | |
Regenxbio Inc | NASDAQ | Healthcare | Biotechnology & Medical Research | 47.4% | US$437.37M | -2.8x | -0.06 | US$8.68 | -4.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Capital Clean Energy | NASDAQ | Industrials | Freight & Logistics Services | 44% | US$1.42B | 41.7x | 0.96 | US$24.23 | 0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -0.9% Downside | Upgrade to Pro+ | |
NYSE | Technology | Software & IT Services | 43.9% | US$26.86B | 232x | 2.15 | US$145.59 | 1.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 3% Upside | Upgrade to Pro+ | ||
Up Fintech | NASDAQ | Financial | Investment Banking & Investment Services | 43.2% | US$1.77B | 21.2x | 0.24 | US$10.04 | -2.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 13.5% Upside | Upgrade to Pro+ | |
NewAmsterdam Pharma | NASDAQ | Healthcare | Biotechnology & Medical Research | 42.5% | US$2.42B | -11.8x | -0.4 | US$21.54 | -2.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Elron Electronic Industries | OTC Markets | Financial | Investment Banking & Investment Services | 40.7% | US$81.20M | 4x | 0.01 | US$1.54 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Critical Metals Corp | NASDAQ | Basic Materials | Metals & Mining | 38.9% | US$310.81M | -1x | US$3 | -1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Abivax ADR | NASDAQ | Healthcare | Biotechnology & Medical Research | 38.5% | US$527.55M | -0.22 | US$8.27 | -0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
DeFi Tech | NASDAQ | Technology | Financial Technology (Fintech) & Infrastructure | 37.7% | US$1.02B | 55.8x | 0.35 | US$3.03 | 2.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Ares Commercial RE | NYSE | Real Estate | Residential & Commercial REITs | 37.3% | US$260.63M | -19.4x | -0.28 | US$4.74 | -2.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 5.5% Upside | Upgrade to Pro+ | |
Volitionrx Ltd | NYSE | Healthcare | Biotechnology & Medical Research | 36.8% | US$68.79M | -2.5x | -0.07 | US$0.67 | -1.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Financial 15 | OTC Markets | Financial | Collective Investments | 36.2% | US$441.37M | 1.7x | US$7.12 | 0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
XOMA | NASDAQ | Consumer Cyclicals | Media & Publishing | 35.9% | US$324.78M | -38x | -0.46 | US$27.14 | -2.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Mirum Pharmaceuticals | NASDAQ | Healthcare | Pharmaceuticals | 33% | US$2.61B | -33.1x | -0.6 | US$52.66 | -0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 37.7% Upside | Upgrade to Pro+ | |
Better Home Finance Holding | NASDAQ | Financial | Banking Services | 32.3% | US$206.78M | -1x | -0.01 | US$13.60 | -4.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Dominari Holdings | NASDAQ | Financial | Investment Banking & Investment Services | 29.9% | US$73.07M | -0.9x | 0.07 | US$4.99 | 4.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Perella Weinberg Partners | NASDAQ | Financial | Investment Banking & Investment Services | 29.9% | US$1.24B | -97.8x | -1.14 | US$20 | -3.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 17.5% Upside | Upgrade to Pro+ | |
China Fund | NYSE | Financial | Collective Investments | 28.5% | US$148.76M | 7.7x | US$14.89 | -0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Canadian General Investments | OTC Markets | Financial | Collective Investments | 28.3% | US$618.25M | 2.8x | US$29.61 | 2.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Dividend 15 Split | OTC Markets | Financial | Investment Banking & Investment Services | 28.2% | US$609.33M | 1.9x | US$4.55 | -0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Tetragon | OTC Markets | Financial | Collective Investments | 26.9% | US$1.35B | 3.9x | US$16.80 | 2.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Invesco Mortgage | NYSE | Real Estate | Residential & Commercial REITs | 25.9% | US$505.12M | 16.1x | 0.11 | US$7.66 | -1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -5.4% Downside | Upgrade to Pro+ | |
ARS Pharmaceuticals | NASDAQ | Healthcare | Biotechnology & Medical Research | 25.9% | US$1.74B | -111.7x | -1.61 | US$17.69 | -1.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Avadel Pharma | NASDAQ | Healthcare | Pharmaceuticals | 25.1% | US$931.21M | -34.3x | -0.42 | US$9.61 | -1.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |